Alnylam Pharmaceuticals (NASDAQ:ALNY) Hits New 52-Week High at $210.85

Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) hit a new 52-week high during mid-day trading on Thursday . The company traded as high as $210.85 and last traded at $210.74, with a volume of 5221 shares traded. The stock had previously closed at $203.89.

Several equities analysts recently weighed in on the company. HC Wainwright raised their price objective on Alnylam Pharmaceuticals from $235.00 to $250.00 and gave the company a “buy” rating in a research note on Friday, August 13th. Chardan Capital reaffirmed a “buy” rating and issued a $190.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Wednesday, August 4th. UBS Group raised Alnylam Pharmaceuticals from a “neutral” rating to a “buy” rating and raised their price objective for the company from $141.00 to $215.00 in a research note on Monday, October 4th. BMO Capital Markets increased their target price on Alnylam Pharmaceuticals from $174.00 to $196.00 and gave the company a “market perform” rating in a report on Friday, August 27th. They noted that the move was a valuation call. Finally, Barclays increased their target price on Alnylam Pharmaceuticals from $196.00 to $216.00 and gave the company an “overweight” rating in a report on Wednesday, August 4th. Six analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $175.86.

The firm has a market capitalization of $24.85 billion, a P/E ratio of -26.86 and a beta of 1.22. The business has a fifty day moving average of $195.16 and a 200-day moving average of $168.52. The company has a debt-to-equity ratio of 0.51, a quick ratio of 4.76 and a current ratio of 4.91.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings data on Monday, August 2nd. The biopharmaceutical company reported ($1.61) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($1.61). Alnylam Pharmaceuticals had a negative return on equity of 88.43% and a negative net margin of 128.96%. The business had revenue of $220.55 million during the quarter, compared to analyst estimates of $193.66 million. During the same period in the prior year, the company posted ($1.67) EPS. The business’s revenue for the quarter was up 112.1% compared to the same quarter last year. On average, equities research analysts forecast that Alnylam Pharmaceuticals, Inc. will post -6.15 earnings per share for the current fiscal year.

In other Alnylam Pharmaceuticals news, CEO John Maraganore sold 33,979 shares of the stock in a transaction on Friday, August 13th. The stock was sold at an average price of $199.78, for a total transaction of $6,788,324.62. Following the completion of the transaction, the chief executive officer now directly owns 248,744 shares of the company’s stock, valued at approximately $49,694,076.32. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Laurie Keating sold 10,000 shares of the stock in a transaction on Thursday, August 5th. The shares were sold at an average price of $188.95, for a total value of $1,889,500.00. Following the sale, the executive vice president now owns 13,008 shares of the company’s stock, valued at approximately $2,457,861.60. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 97,043 shares of company stock valued at $19,237,561. 2.30% of the stock is currently owned by corporate insiders.

Large investors have recently made changes to their positions in the company. Koshinski Asset Management Inc. acquired a new stake in shares of Alnylam Pharmaceuticals during the 3rd quarter valued at $44,000. Wolverine Asset Management LLC lifted its holdings in shares of Alnylam Pharmaceuticals by 3,023.1% in the first quarter. Wolverine Asset Management LLC now owns 406 shares of the biopharmaceutical company’s stock valued at $57,000 after purchasing an additional 393 shares in the last quarter. IFP Advisors Inc lifted its holdings in shares of Alnylam Pharmaceuticals by 914.3% in the second quarter. IFP Advisors Inc now owns 355 shares of the biopharmaceutical company’s stock valued at $60,000 after purchasing an additional 320 shares in the last quarter. HM Payson & Co. lifted its holdings in shares of Alnylam Pharmaceuticals by 121.4% in the first quarter. HM Payson & Co. now owns 465 shares of the biopharmaceutical company’s stock valued at $66,000 after purchasing an additional 255 shares in the last quarter. Finally, Capital Analysts LLC purchased a new stake in shares of Alnylam Pharmaceuticals in the second quarter valued at $68,000. Institutional investors own 93.34% of the company’s stock.

About Alnylam Pharmaceuticals (NASDAQ:ALNY)

Alnylam Pharmaceuticals, Inc operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. The firm’s products include ONPATTRO, GIVLAARI, and OXLUMO. It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases.

Further Reading: What is the quiet period?

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.